Study Demonstrates Percutaneous Tibial Nerve Stimulation Offers
More Cost-Effective OAB Treatment Than Sacral Nerve Stimulation
MINNEAPOLIS, Dec. 6, 2012 /PRNewswire/ -- Uroplasty, Inc.
(NASDAQ:UPI), a medical device company that develops, manufactures
and markets innovative proprietary products for the treatment of
voiding dysfunctions, today highlighted results of a study that
compared the cost effectiveness of neuromodulation therapies for
Overactive Bladder (OAB) patients over two years of treatment.
The study compared percutaneous tibial nerve stimulation
(PTNS) delivered via Uroplasty's Urgent® PC
Neuromodulation System versus sacral nerve stimulation (SNS). The
article, "Costs of Neuromodulation Therapies for Overactive
Bladder: Percutaneous Tibial Nerve Stimulation Versus Sacral Nerve
Stimulation," will be published in the January 2013 edition of The Journal of
Urology. An abstract is now available online at
http://dx.doi.org/10.1016/j.juro.2012.08.085.
The study used average Medicare national reimbursement amounts
for the cost evaluation of these two neuromodulation therapies with
clinically comparable outcomes. The initial cost of PTNS therapy
was $1,773 for 12 weekly treatments
compared to $1,857 for the SNS test
stimulation. Over two years, the cumulative discounted costs
for PTNS therapy were estimated to be $3,850 compared to the SNS implant at
$14,160. Under a wide variety
of conditions, PTNS remained significantly less costly than SNS
over two years of therapy for those patients with OAB refractory to
conservative and drug therapy.
Melissa Martinson, PhD, lead
author of the study stated, "This study demonstrates significant
cost savings to the healthcare system when PTNS is used instead of
SNS. In our current U.S. healthcare climate, maintaining the
quality of care while also controlling costs is a central
objective. We believe that studies like this can contribute
to attaining that goal."
"This study demonstrates that PTNS remains a better value than
SNS for OAB therapy for those patients who progress to
neuromodulation therapy to treat their OAB symptoms," said
Dave Kaysen, President and Chief
Executive Officer of Uroplasty, Inc. "By demonstrating the cost
over two years of SNS treatment for 100 patients was $1.4 million compared to approximately
$385,000 for PTNS, we believe this
study will interest payers who are now more attuned to comparative
effectiveness research to determine the most cost-effective OAB
care algorithm."
About the Urgent® PC Neuromodulation
System
The Urgent PC Neuromodulation System is proprietary, minimally
invasive, percutaneous tibial nerve stimulation (PTNS) device
designed for office-based treatment of overactive bladder (OAB) and
the associated symptoms of urinary urgency, urinary frequency and
urge incontinence.
About Uroplasty, Inc.
Uroplasty, Inc., headquartered in Minnetonka, Minnesota, with wholly-owned
subsidiaries in The Netherlands
and the United Kingdom is a global
medical company committed to offering transformative treatment
options to specialty physicians. Our products are designed to
help providers change the lives of their voiding dysfunction
patients and strengthen the efficiency of their practices. Our
focus is the continued commercialization of our Urgent® PC
Neuromodulation System, the only FDA-cleared system that delivers
percutaneous tibial nerve stimulation (PTNS) for the office-based
treatment of overactive bladder and associated symptoms of urgency,
frequency and urge incontinence. We also offer
Macroplastique®, an injectable urethral bulking agent
for the treatment of adult female stress urinary incontinence
primarily due to intrinsic sphincter deficiency. For more
information on the company and its products, please visit
Uroplasty, Inc. at www.uroplasty.com.
Forward-Looking Information
This press release contains forward-looking statements that
reflect our best estimates regarding future events and financial
performance. These forward-looking statements are subject to
risks and uncertainties that could cause actual results to differ
materially from our anticipated results. We discuss in detail
the factors that may affect the achievement of our forward-looking
statements in our Annual Report on Form 10-K filed with the
SEC. In particular, we cannot be certain that the rate of
reimbursement for PTNS treatments will be adequate to justify the
cost of our product, that other Medicare carriers or private payers
will provide coverage for this treatment, or that any of the other
risks identified in our 10-K will not adversely affect our
expectations as described in these forward-looking statements.
For
Further Information:
Uroplasty,
Inc.
David
Kaysen, President and CEO, or
Medi
Jiwani, Vice President, CFO, Treasurer
952.426.6140
|
EVC
Group
Doug
Sherk/Jenifer Kirtland
(Investors), 415.896.6820
Chris Gale
(Media), 646.201.5431
|
SOURCE Uroplasty, Inc.